SMC makes recommendations on Resolor, Prolia, Avelox IV and Ranexa
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC), Scotlands health technology assessment group, this week rejected Movetis's Resolor (prucalopride) for the symptomatic treatment of chronic constipation in women who do not find adequate relief from laxatives. This was down to weaknesses in the clinical data submitted by the company and a failure to present a suitably robust economic analysis, said the SMC.